Author of

• 15343

  +

  P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Locoregional Disease – NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15346

    +

    P3.03-003 - Pilot Introduction of the IASLC Nodal Classification System across EBUS-TBNA, CT and PET in Staging of Non Small Cell Lung Cancer (ID 991)

    09:30 - 09:30  |  Author(s): L. Emmett
    • Abstract
    • Slides

    Background:
    The accurate reporting of lymph node status is important in the staging and subsequent management of primary non small cell (NSCLC) lung cancer. However, lymph node nomenclature varies widely across staging modalities and between operators. Nodal stage may therefore be lost in translation when interpreting reports, compromising accuracy and possibly patient care. The International Association for the Study of Lung Cancer (IASLC) system of lymph node classification facilitates standardized, accurate identification of mediastinal lymph node groups. Preliminary work at our institution indicates a low uptake of this classification system in staging modalities, particularly CT and PET/CT. Application of this classification system across staging modalities may improve consistency of staging in primary NSCLC.Aim To determine the feasibility and impact of prospectively introducing the IASLC nodal classification system in a retrospectively identified series of NSCLC cases
    
    Methods:
    A series of cases of NSCLC (n=54) with IASLC classification at EBUS-TBNA identified in preliminary work will be reviewed. A sub-group will be selected that have had both other key staging modalities (CT and PET/CT) at our institution. IASLC classification will be applied retrospectively to two other key staging modalities, CT and PET/CT, by study investigators.
    
    Results:
    The primary endpoint for analysis is change in final nodal stage before and after the application of IASLC classification. Secondary endpoints include (i) change in IASLC classification between PET/CT and EBUS-TBNA, (ii) change in IASLC classification between CT and PET/CT, (iii) change in IASLC classification between CT and EBUS-TBNA.
    
    Conclusion:
    The effect of introducing IASLC lymph node classification across three staging modalities in NSLC (CT, PET/CT and EBUS-TBNA) will be presented.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.